









2.3. CEPHELOSPORIN

These are β -lactam antibiotics closely related (structurally and functionally) to the penicillins. Cephalosporins have 7-amino cephalosporanic acid nucleus and are obtained from the fungus *Cephalosporium*.




2.3.1. Introduction, History & Development

-  In 1945, Giuseppe Brotzu's discovery found that *Cephalosporium acremonium* cultures inhibited the growth of wide variety of Gram-positive and Gram-negative bacteria.
-  The cephalosporins were isolated from the fungus *Cephalosporium acremonium* in 1948 by Pro Tzu, Newton, and Abraham (1953).
-  The molecular modification of cephalosporin-C (Main Product) gave origin to semisynthetic substances.
-  The development was started after modification of 7-ACA side chains with cephalothin as the first drug introduced by Eli Lilly and Company in 1964.
-  Cephalosporins have similar fundamental structural requirements (β -lactam) as penicillin with little differences, it has cephems (dihydro 1,3 thiazene ring fused with β -lactam) ring while penicillin has penam ring.
-  It has also similar mechanism of action as penicillin they mainly inhibit the cross-linking of the peptidoglycan units in bacterial cell walls by inhibiting transpeptidase enzyme. However, they bind in the target proteins other than penicillins binding proteins.
-  The cephalosporins are much more acid stable than the corresponding penicillins





Cephalosporins can be divided into three classes:

1. *Cephalosporin N*: It has a penicillin-like structure being a derivative of 6-aminopenicillanic acid.




Cephalosporin N

2. *Cephalosporin P*: An acidic antibiotic, which is steroidal in nature.



Cephalosporin P

3. *Cephalosporin-C*: It is a true cephalosporin and it is a derivative of 7-aminocephalosporanic acid, alpha-amino adipic acid.




Cephalosporin-C

2.3.2. Structure and Nomenclature

System 1:

Cephem: 5-Thia-1-azobicyclo (4.2.0) oct-2-ene-8-one system




Cephem

8-oxa-5-Thia-1-azobicyclo (4.2.0) oct-2-ene-2- carboxylic acid

(Cephem-2- carboxylic acid)

Example:

Cephalothin




Cephalothin

3-(Acetoxy methyl)-8-oxo-7-(2-thienyl) acetamido-5thia-1-aza-bicyclo[4.2.0]-oct-2ene-2-carboxylic acid

System 2


Cephem: 1-Thia-5-azobicyclo (4.2.0) oct-3-ene-8-one system



Cephem


8-oxa-1-Thia-5-azobicyclo (4.2.0) oct-3-ene-4- carboxylic acid
(Cephem-4- carboxylic acid)

Cephalothin




3-(Acetoxy methyl)-8-oxo-7-(2-thienyl) acetamido-1-thia-5-aza-bicyclo[4.2.0]-oct-3-ene-4-carboxylic acid

System 3: By using Cephem or cephalosporanic acid



7-amino cephalosporanic acid


Cephalothin



Cephalothin

7-(2-thienyl) acetamido- cephalosporanic acid

Cephalosporin C




Cephalosporin-C

7-alfa-amino adipic amino or

7-(5-amino-5-cabboxy valiramido)- cephalosporanic acid


2.3.3. Stereochemistry



Cephalosporin

- Chiral Centre: at C6 and C7
- Absolute Configuration: 6R:7R


2.3.4. Structural Activity Relationship of Cephalosporin



1. β -lactam ring essential required for PBP reactivity, antibacterial activity, mechanism of action, and drug resistance
2. There are several sites for modification: A) Acylamino side chain, B) C-3 substitution, C) Sulfur atom, D) Carboxy group at C-4

A. Acylamino Substitution (R1)

1. Phenyl Glycyl Group [$C_6H_5-CH(NH_2)-COOH$]: The addition of amino group and a hydrogen to α and $\alpha 1$ position produces basic compound, which is protonated under acidic conditions of stomach. The ammonium ion improves the stability of β -lactum of cephalosporins and make active orally. Activity against positive bacteria is increased and gram negative is decreased by acylation of amino group. E.g. **Orally Active**: cephalixin, cephradine, and cefaclor



2. When the new acyl groups are derived from carboxylic acids, it shows good spectrum of antibacterial action for gram-positive bacteria.


- Substitutions on the aromatic ring phenyl that increase lipophilicity provide higher gram-positive activity and generally lower gram-negative activity.
- The phenyl ring in the side chain can be replaced with other **heterocycles** with improved spectrum of activity and pharmacokinetic properties; these include thiophene (Cephalothin, Cephaloridine) tetrazole (Cefazolin), furan (Cefuroxime), and pyridine (Cephapirin).
- Introducing of methoxy imine or N-alkoxy acid imine increase the gram -ve activity and decrease the gram +ve activity. E.g., **Methoxy imines:** Cefuroxime, Cefotaxime, Ceftizoxime, Ceftriaxone. **N-alkoxy imine:** Cefixime and Ceftazidime






- The L-isomer of an α -amino α 1-hydrogen derivative of cephalosporins was 30–40 fold stable than D-isomer.

B. R2 Substitution at C-3

- Alteration on R2 interfere the chemical/acid stability/instability/pharmacokinetic properties.

| | | |
|--|---|--|
| -H, -CH ₃ , -Cl, -CH ₂ OCH ₃ -CH=CHR Acid stable, metabolic stable, oral active derivatives | -CH ₂ OCOCH ₃ Acid and Metabolic unstable Orally inactive E.g., Cephalothin, Cephapirin, Cefotaxime | -CH ₂ OCONH ₂ Acid unstable Little metabolic stable Orally inactive e.g., Cefuroxime, Cefoxitin |
| $\begin{array}{c} \text{---CH}_2\text{---S---} \\ \quad \quad \quad \\ \text{N} \quad \quad \quad \text{N} \end{array}$ thio-thiadiazole Acid unstable, metabolic stable, oral inactive e.g. Cefazolin | $\begin{array}{c} \text{---CH}_2\text{---S---} \\ \quad \quad \quad \\ \text{N} \quad \quad \quad \text{N} \\ \quad \quad \quad \\ \text{H}_3\text{C} \quad \quad \quad \text{H} \end{array}$ Thio-triazine Acid Stable, somewhat metabolic stable, orally inactive e.g. Ceftriaxone |  Acid Stable, somewhat metabolic stable, poorly oral active e.g. Cefaloridine, Ceftazidime |

| | | |
|---|---|--|
|  <p>Oral inactive Anti-pseudomonal activity E.g., Cefepime</p> |  <p>N-methyl thio-tetrazole E.g., Cefamandole, Cefotetan, Cefoperazone Metabolic stable Acid Unstable Not orally Active</p> |  <p>thio-tetrazole-1-lactic acid E.g., Ceforanide Metabolic stable Acid Unstable Not orally Active</p> |
|---|---|--|

2. Heterocyclic substitution enhance protein binding and half life

3. The benzoyl ester displays improved gram-positive activity, but lowered gram-negative activity.

4. Pyridine, imidazole replaced acetoxy group by azide ion yields derivative with relatively low gram-negative activity

C. Others

1. Double bond between C3-C4 is essential for activity, changing the position may lead to loss of activity.

2. Oxidation of S atom may lead to decrease the activity

3. replace the S atom with O enhanced the antibacterial activity


4. Carboxy group at C-4 helps to preparation of Salt and Prodrug to enhance the oral bioavailability.

5. Methoxy group at C-7, shows higher resistance to hydrolysis by β -lactamase


2.3.5. Chemical Degradation of Cephalosporin

Similar to penicillin, cephalosporin undergoes variety of hydrolytic degradation


A. In the presence of strong acid



B. In the presence of beta-lactamase enzyme






C. In the presence of acylase




2.3.6. Classification and Important Products


(1) First Generation Cephalosporins:


-  These have greater activity against gram positive and less activity against gram negative microorganisms.
-  These are effective against *E.coli*, *Proteus*, *Klebsiella*, *Staphylococci*, *Streptococci* and *Pneumococci*.


 These are ineffective against *Salmonella*, *Shigella*, *Anaerobes* and *Pseudomonas*. These were developed in 1960s.

 e.g. Cefazolin, Cephalexin, Cephalothin, Cephaloridine, Cephradine, Cefadroxil and Cephapirin.


(2) Second Generation Cephalosporins :


 These have greater activity against gram negative microorganism including *H. influenza*, *Enterobacter aerogenes* and some *Neisseria species*.

 Second generation cephalosporins were introduced subsequent to first generation cephalosporins. These are inactive against *anaerobes* and *Pseudomona aerugionosa*.


 e.g. Cefaclor, Cefoxitin, Cefamandole and Cefuroxime.


(3) Third Generation Cephalosporins:


 These antibiotics offer wider coverage against gram negative bacilli and are less active on gram positive cocci. These were introduced in 1980s.


 e.g. Cefixime, Ceftriaxone, Cefotaxime, Ceftrazidime, Ceftizoxime and Cefoperazone.

(4) Fourth Generation Cephalosporins:

 These are newly developed cephalosporins, have same properties like those of third generation cephalosporins but more resistant to β -lactamases.








 Fourth generation cephalosporins are inactive against methicillin resistant *Staphylococci*.








 e.g. Cefepime and Cefprome.



Basic Ring of Cephalosporin

| COMPOUND | R2 at C3 | R1 at C7 | IUPAC NAME | DOSE | USE |
|---------------------------|------------------|----------|---|--|---|
| FIRST GENERATION | | | | | |
| 1. Cefazolin ^s | | | 3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 250-500 mg i.m./i.v. every 8 hr. | Used in infections caused by <i>Klebsiella</i> , <i>E.coli</i> and <i>P. mirabilis</i> . |
| 2. Cephalexin* | -CH ₃ | | 7-[[2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 250 mg -1g. every 8 hr. | Used in the infections caused by <i>Streptococci</i> , <i>Staphylococci</i> , <i>Gonococci</i> , <i>Meningococci</i> , <i>C. diphtheriae</i> , <i>Clostridia</i> , <i>E. Coli</i> , <i>Klebsiella</i> , <i>Salmonella</i> etc. (less active against penicillinase producing <i>Staphylococci</i> and <i>H. influenzae</i>). |

| | | | | | |
|-------------------------------|--|---|---|---|---|
| 3. Cephalothin ^s | -CH ₂ - OCO - CH ₃ |  | 3-(acetyloxymethyl)-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 1-2 g i.v. 6 hr. (i.m. is very painful). | Used mainly in infections caused by <i>penicillinase</i> producing <i>Staphylococci</i> . |
| 4. Cephaloridine ^s | -CH ₂ -  |  | 8-oxo-3-(pyridin-1-ium-1-ylmethyl)-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | 0.5 - 2 g i.m. or i.v. 6-12 hr. | Similar to cephalixin (highly susceptible to β -lactamases). |
| 5. Cephadrine [#] | - CH ₃ |  | 7-[[[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 250 mg-1g. oral/ im/i.v. two to four times daily. | Similar to cephalixin |
| 6. Cefadroxil* | - CH ₃ |  | 7-[[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 500 mg - 1 g two times daily. | Similar to cephalixin |
| 7. Cephapirin ^s | -CH ₂ - O - CO - CH ₃ |  | 3-(acetyloxymethyl)-8-oxo-7-[(2-pyridin-4-ylsulfanylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 1 - 2 g 6 hr. (i.m. is very painful). | Similar to cephalothin |
| SECOND GENERATION | | | | | |
| 8. Cefaclor* | -Cl |  | 7-[[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 250-500 mg every 8 hr. | Used in the infections caused by <i>H. influenzae</i> <i>E.coli</i> and <i>P. mirabilis</i> . |

| | | | | | |
|------------------------------|--|---|---|---|---|
| 9. Cefoxitin ^s | -CH ₂ - OCONH ₂ |  | 3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 1-2 g im/i.v 6-8 hr. | Used in the infections caused by <i>B. fragilis</i> , <i>Serratia</i> and indole positive <i>Proteus</i> (Highly resistant to β -lactamases). |
| 10. Cefamandole ^s | -CH ₂ -S-  |  | 7-[[[(2 <i>R</i>)-2-hydroxy-2-phenylacetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 1-2g im/iv 6 hr. | Used in the infections caused by <i>H.influenzae</i> , <i>Klebsiella</i> , <i>E.coli</i> , indole positive <i>Proteus</i> and <i>Enterobacter</i> . |
| 11. Cefuroxime ^s | -CH ₂ -O-CO-NH ₂ |  | 3-(carbamoyloxymethyl)-7-[[[(2 <i>Z</i>)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 250 – 500 mg 12 hr. | It is active against <i>H. influenzae</i> , <i>Meningococci</i> & <i>Pneumococci</i> . It is also used in gonorrhoea. |
| THIRD GENERATION | | | | | |
| 12. Cefixime* | - CH = CH ₂ |  | 7-[[[(2 <i>Z</i>)-2-(2-amino-1,3-thiazol-4-yl)-2-(carboxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 200 mg every 12 hr. or 400 mg once a day. | Used in the infections caused by <i>E.coli</i> , <i>Klebsiella</i> , <i>H. influenzae</i> , <i>M.catarrhalis</i> , <i>N. gonorrhoea</i> & <i>N.meningitidis</i> . |
| 13. Ceftriaxone ^s |  |  | 7-[[[(2 <i>Z</i>)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1 <i>H</i> -1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 500 mg – 1 g every 12 hr. | Used in gonorrhoea and infections, caused by <i>H.influenzae</i> , <i>N.meningitidis</i> and <i>Strep. pneumoniae</i> . |

| | | | | | |
|-------------------------------|----|--|--|------------------------------------|---|
| 14. Cefotaxime [§] | | | 3-(acetyloxymethyl)-7-[[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 1-2g i.m./iv every 6-12 hr. | It is active against anaerobic gram negative and gram positive bacteria. |
| 15. Ceftazidime [§] | | | 7-[[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | 500 mg – 2 g i.m./i.v. every 8 hr. | Highly active against <i>Pseudomonas</i> . It is also active against <i>Enterobacteriaceae</i> . |
| 16. Ceftizoxime [§] | -H | | 7-[[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 500 mg–1g i.m./i.v. every 8-12 hr | Similar to cefotaxime. |
| 17. Cefoperazone [§] | | | 7-[[[(2R)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetyl]amino]-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | 1 – 2g i.m./i.v. every 12 hr. | Most active against <i>Pseudomonas</i> . Used in the treatment of infections caused by <i>S.typhi</i> and <i>B. fragilis</i> (suseptible to β -lactamases). |

* Administered orally, § Administered parenterally, # *Cephadrine is the only cephalosporin available both for oral and parenteral administration*

By Rajesh Choudhary